387 related articles for article (PubMed ID: 34711366)
1. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
[TBL] [Abstract][Full Text] [Related]
3. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H; Cook G; Goodall S; Liew D
Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
[TBL] [Abstract][Full Text] [Related]
4. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
[TBL] [Abstract][Full Text] [Related]
5. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
[TBL] [Abstract][Full Text] [Related]
6. Estimation of Health-Related Utilities for
Soare IA; Leeuwenkamp O; Longworth L
Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
[TBL] [Abstract][Full Text] [Related]
7. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
[TBL] [Abstract][Full Text] [Related]
8. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Leeuw IMV; Siersema PD; Gamper EM
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38483665
[TBL] [Abstract][Full Text] [Related]
9. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
11. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
12. Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire.
Shiroiwa T; King MT; Norman R; Müller F; Campbell R; Kemmler G; Murata T; Shimozuma K; Fukuda T
Qual Life Res; 2024 Jul; 33(7):1865-1879. PubMed ID: 38724771
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
14. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis.
Koszorú K; Hajdu K; Brodszky V; Bató A; Gergely LH; Kovács A; Beretzky Z; Sárdy M; Szegedi A; Rencz F
Eur J Health Econ; 2023 Feb; 24(1):139-152. PubMed ID: 35412162
[TBL] [Abstract][Full Text] [Related]
15. Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping.
Yang M; Vioix H; Hook ES; Hatswell AJ; Batteson RL; Gaumond BR; O'Brate A; Popat S; Paik PK
Value Health; 2023 Aug; 26(8):1155-1163. PubMed ID: 36805576
[TBL] [Abstract][Full Text] [Related]
16. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
17. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
18. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
19. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
Herdman M; Kerr C; Pavesi M; Garside J; Lloyd A; Cubi-Molla P; Devlin N
J Patient Rep Outcomes; 2020 Mar; 4(1):22. PubMed ID: 32219576
[TBL] [Abstract][Full Text] [Related]
20. Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy.
Bhadhuri A; Kind P; Salari P; Jungo KT; Boland B; Byrne S; Hossmann S; Dalleur O; Knol W; Moutzouri E; O'Mahony D; Murphy KD; Wisselink L; Rodondi N; Schwenkglenks M
Health Qual Life Outcomes; 2020 Sep; 18(1):317. PubMed ID: 32993637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
